UK approves Eli Lilly's Foundayo oral weight-loss pill

Foundayo Eli Lilly weight-loss pill GLP-1 MHRA approval

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Eli Lilly’s Foundayo (orforglipron), making the United Kingdom the first European nation to authorize an oral GLP-1 receptor agonist for both weight management and type 2 diabetes treatment.

Foundayo is a once-daily pill that can be taken without food or water restrictions, offering a convenient alternative to the injectable GLP-1 treatments that currently dominate the market. The medication is authorized for adults with a BMI of 30 or above, or those with a BMI between 27 and 30 who have at least one weight-related health condition. It is also indicated to improve glycemic control in adults with type 2 diabetes.

While the MHRA has granted regulatory approval, the drug is not yet available through the National Health Service (NHS). Access via the public health system depends on a pending assessment by the National Institute for Health and Care Excellence (NICE). Initially, the medication is expected to be available through private prescriptions. Eli Lilly has indicated that the pill's list price in the UK is expected to be lower than its injectable counterpart, Mounjaro.

Entities

Eli Lilly · Foundayo · MHRA · Medicines and Healthcare products Regulatory Agency · NICE · National Institute for Health and Care Excellence · Novo Nordisk · Orforglipron · United Kingdom

Claims

What the coverage asserts, and how many sources carry each claim.

[● 4 SOURCES] The medicine will now need to be assessed by the National Institute for Health and Care Excellence (NICE) to decide whether it should be recommended for NHS use. www.easterneye.biz · longevity.technology · www.share-talk.com · www.larazon.es
[● 3 SOURCES] Foundayo belongs to the GLP-1 class of medicines, which work on the body's appetite and blood sugar regulation systems. www.easterneye.biz · longevity.technology · oglobo.globo.com
[● 3 SOURCES] Foundayo is authorized for adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related health condition. www.easterneye.biz · longevity.technology · www.larazon.es
[● 2 SOURCES] A spokesperson for Eli Lilly stated that the pill will have a lower list price in the UK than the injectable Mounjaro. adevarul.ro · hotnews.ro
[● 3 SOURCES] The MHRA approved Eli Lilly’s orforglipron, sold under the brand name Foundayo, on August 10 for weight management and to improve blood sugar control in adults with type 2 diabetes. www.easterneye.biz · longevity.technology · www.larazon.es
[● 2 SOURCES] Studies indicate that orforglipron can lead to a weight loss of up to 15% over 36 weeks. oglobo.globo.com · www.spacemoney.com.br
[● 3 SOURCES] The UK has become the first European nation to approve a new daily weight-loss pill. www.easterneye.biz · longevity.technology · www.larazon.es
[● 3 SOURCES] The tablet is taken once a day and, unlike some existing oral GLP-1 medicines, it does not require patients to take it at a particular time in relation to food or follow specific water restrictions. www.easterneye.biz · longevity.technology · www.larazon.es